CN116390725A - 用于治疗肺部炎症和间质性肺病的羟基吡格列酮 - Google Patents
用于治疗肺部炎症和间质性肺病的羟基吡格列酮 Download PDFInfo
- Publication number
- CN116390725A CN116390725A CN202180043546.3A CN202180043546A CN116390725A CN 116390725 A CN116390725 A CN 116390725A CN 202180043546 A CN202180043546 A CN 202180043546A CN 116390725 A CN116390725 A CN 116390725A
- Authority
- CN
- China
- Prior art keywords
- thiazolidine
- dione
- ethoxy
- phenyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382356 | 2020-04-30 | ||
| EP20382356.2 | 2020-04-30 | ||
| PCT/IB2021/053651 WO2021220250A1 (en) | 2020-04-30 | 2021-04-30 | Leriglitazone for treating lung inflammation and interstitial lung disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116390725A true CN116390725A (zh) | 2023-07-04 |
Family
ID=70779625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180043546.3A Pending CN116390725A (zh) | 2020-04-30 | 2021-04-30 | 用于治疗肺部炎症和间质性肺病的羟基吡格列酮 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230172921A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4142720A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023525981A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230035522A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116390725A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021265345A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022021951A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3180351A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297771A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013021A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021220250A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020013181A (es) | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. |
| JP2026500743A (ja) * | 2022-12-28 | 2026-01-08 | ミノリックス セラピューティクス エセ.エレ. | レリグリタゾンの最適投薬 |
| WO2024231881A2 (en) * | 2023-05-09 | 2024-11-14 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010150014A1 (en) * | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| WO2011073662A1 (en) * | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
| US20200093812A1 (en) * | 2016-12-01 | 2020-03-26 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-Hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for Treating Nonalcoholic Fatty Liver Disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2222272B1 (en) * | 2008-08-07 | 2012-11-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| US20120190637A1 (en) * | 2009-10-14 | 2012-07-26 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
| NZ725492A (en) | 2014-04-02 | 2023-06-30 | Minoryx Therapeutics S L | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| MX2020013182A (es) * | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales. |
-
2021
- 2021-04-30 CN CN202180043546.3A patent/CN116390725A/zh active Pending
- 2021-04-30 WO PCT/IB2021/053651 patent/WO2021220250A1/en not_active Ceased
- 2021-04-30 US US17/997,393 patent/US20230172921A1/en not_active Abandoned
- 2021-04-30 AU AU2021265345A patent/AU2021265345A1/en not_active Abandoned
- 2021-04-30 MX MX2022013021A patent/MX2022013021A/es unknown
- 2021-04-30 JP JP2022566063A patent/JP2023525981A/ja active Pending
- 2021-04-30 KR KR1020227042096A patent/KR20230035522A/ko not_active Abandoned
- 2021-04-30 BR BR112022021951A patent/BR112022021951A2/pt not_active IP Right Cessation
- 2021-04-30 IL IL297771A patent/IL297771A/en unknown
- 2021-04-30 CA CA3180351A patent/CA3180351A1/en active Pending
- 2021-04-30 EP EP21723015.0A patent/EP4142720A1/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010150014A1 (en) * | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| WO2011073662A1 (en) * | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
| US20200093812A1 (en) * | 2016-12-01 | 2020-03-26 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-Hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for Treating Nonalcoholic Fatty Liver Disease |
Non-Patent Citations (3)
| Title |
|---|
| ELENA CARBONI ET AL: "Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?", MEDICAL HYPOTHESES, no. 140, 22 April 2020 (2020-04-22), pages 2 * |
| UWE MEYA ET AL: "A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Biomarkers of MIN-102 (Leriglitazone) (4149)", NEUROLOGY, no. 94, 14 April 2020 (2020-04-14) * |
| 吴荣;孙宇楠;张振勇;曾越灿;曹硕;: "吡格列酮在大鼠放射性肺纤维化中保护作用的研究", 实用药物与临床, no. 01, 15 January 2015 (2015-01-15) * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4142720A1 (en) | 2023-03-08 |
| US20230172921A1 (en) | 2023-06-08 |
| MX2022013021A (es) | 2023-01-16 |
| IL297771A (en) | 2022-12-01 |
| CA3180351A1 (en) | 2021-11-04 |
| BR112022021951A2 (pt) | 2022-12-13 |
| AU2021265345A1 (en) | 2022-12-08 |
| JP2023525981A (ja) | 2023-06-20 |
| KR20230035522A (ko) | 2023-03-14 |
| WO2021220250A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230241014A1 (en) | Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm | |
| US11364227B2 (en) | Sphingosine kinase 2 inhibitor for treating coronavirus infection | |
| US20260041660A1 (en) | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | |
| US20230218596A1 (en) | Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection | |
| US20230172921A1 (en) | Leriglitazone for treating lung inflammation and interstitial lung disease | |
| US20230157994A1 (en) | New compositions and methods of treating covid-19 disease | |
| Pickering et al. | Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages | |
| HK40096631A (en) | Leriglitazone for treating lung inflammation and interstitial lung disease | |
| US20150165009A1 (en) | Tlr5 ligands, therapeutic methods, and compositions related thereto | |
| KR20230021009A (ko) | 항바이러스 치료로서의 아젤라스틴 | |
| EP4183396A1 (en) | Use of a nitrogen-containing bisphosphonate in combination with a glucocorticoid in preventing or treating viral pneumonia | |
| WO2016149045A1 (en) | Reversal of latency of retroviruses with a galectin protein | |
| EP3720440A1 (en) | Treatment of rsv with combination product | |
| WO2023280828A1 (en) | A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation | |
| US11471448B2 (en) | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia | |
| RU2837859C1 (ru) | Лечение коронавирусной инфекции | |
| US20240165096A1 (en) | Anti Viral Therapy | |
| WO2025235945A1 (en) | Methods of treating viral infections using a fusion inhibitor | |
| EA051538B1 (ru) | Ингибиторы mek для лечения или предупреждения коронавирусных инфекций и/или цитокинового шторма при covid-19 | |
| WO2023084489A1 (en) | Methods of treating coronavirus disease 2019 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40096631 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20230704 |